ABSTRACT
@#Objective: To investigate the expression of metastasis-associated protein 2 (MTA2) in human bladder cancer tissues and its effect on the malignant biological behaviors of bladder cancer T24 cells, as well as to explore the effect of MTA2 on the progression of bladder cancer. Methods: Sixty-two cases of human bladder cancer tissues and 28 cases of normal bladder tissues (from patients with cystitis, and pathologically confirmed as normal tissue) were collected at People’s Hospital of Hebei Province during December 2012 and December 2014. The expression of MTA2 in bladder cancer tissues and normal bladder tissues was detected by immunohistochemical staining, and the correlation between MTA2 expression and clinicopathological characteristics of patients was also analyzed. The bladder cancer T24 cell line stably expressing MTA2 was constructed. The effects of MTA2 on the proliferation, colony formation, migration and invasion of bladder cancer T24 cells were detected by MTS, clone formation, scratch healing and Transwell assay, respectively. Results: Immunohistochemical staining showed that MTA2 expression was significantly up-regulated in bladder cancer tissues as compared with normal bladder tissues (P<0.01). The high expression of MTA2 in bladder cancer tissues was not related to gender, age and tumor volume (P>0.05), but was associated with higher TNM stage, histological grade, and lymphatic infiltration and metastasis (all P<0.05). After over-expression of MTA2 in bladder cancer T24 cell line, the proliferation activity of the cells was significantly increased (P<0.05), and the colony formation, scratch healing, migration and invasion ability were significantly increased (all P<0.01). Conclusions: MTA2 is up-regulated in human bladder cancer tissues and can promote the proliferation, tumor formation, migration and invasion of T24 cells.
ABSTRACT
Purpose To analyze the expression and prognostic value of metastasis-associated protein 2 (MTA2) in epithelial ovarian carcinoma. Methods The expression of MTA2 protein was examined in 91 paraffin-embedded specimens by immunohistochemical SP method, and in fresh specimens by Western blot, and then combined with follow-up data for prognosis analysis. Results There was an increasing tendency in positive rate of MTA 2 expression from benign ovarian cysts (17.5％) to epithelial ovarian cancers (78.43％), and there were significant difference (χ2=33.328, P<0.001). The expression of the MTA2 was significantly correlated to FIGO stage and lymph node metastasis (both P<0.05). The relative expression of MTA2 in benign ovarian cysts and epithelial ovarian cancers was 0.58±0.05, and 1.22±0.10, respectively, and the difference was statistically significant (t=-22.274, P<0.001). The survival curve of patients with MTA2 (+) differed from the survival curve of patients with MTA2 (-) and the difference was statistically significant (χ2=10.203, P<0.05). The multiple factor analysis revealed that the expression of MTA2, FIGO stage and lymph node metastasis were independent prognostic factors for clinical outcome of epithelial ovarian cancer. Conclusion MTA2 may be involved in the progression and metastasis of epithelial ovarian cancer as an oncogene. Overexpression of the marker indicates poor prognosis of patients.
ABSTRACT
Objective·To explore the expression of MTA2 in endometrial carcinomas and its correlation with clinicopathological features.Methods·The GCBI database was used to analyse the MTA2 expression in most cancers.Immunohistochemical staining of MTA2,p53,ER,PR and Ki-67 was performed in 119 endometrial carcinomas tissues and 21 corresponding adjacent non-neoplastic endometria.And the correlation between MTA2 expression and clinicopathological characteristics was evaluated as well as the correlation between MTA2 expression and the expression of ER,PR,p53 or Ki-67.Results·The expression of MTA2 was up-regulated in most of the tumors including endometrial carcinomas in GCBI database.MTA2 was overexpressed in endometrial carcinoma compared with the adjacent normal tissues (P=0.000),and the expression level was related to tumor grade (x2=8.072,P=0.018) and Ki-67 expression (r=0.227,P=0.013).Conclusion·MTA2 may act as an oncogene in endometrial carcinomas,and it is a promising target for diagnosis and treatment of endometrial carcinomas.
ABSTRACT
Objective: To explore the expression of MTA2 in endometrial carcinomas and its correlation with clinicopathological features. Methods: The GCBI database was used to analyse the MTA2 expression in most cancers. Immunohistochemical staining of MTA2, p53, ER, PR and Ki- 67 was performed in 119 endometrial carcinomas tissues and 21 corresponding adjacent non-neoplastic endometria. And the correlation between MTA2 expression and clinicopathological characteristics was evaluated as well as the correlation between MTA2 expression and the expression of ER, PR, p53 or Ki-67. Results: The expression of MTA2 was up-regulated in most of the tumors including endometrial carcinomas in GCBI database. MTA2 was overexpressed in endometrial carcinoma compared with the adjacent normal tissues (P=0.000), and the expression level was related to tumor grade (χ2=8.072, P=0.018) and Ki-67 expression (r=0.227, P=0.013). Conclusion: MTA2 may act as an oncogene in endometrial carcinomas, and it is a promising target for diagnosis and treatment of endometrial carcinomas.
ABSTRACT
In order to investigate the roles of MTA2 in the pathogenesis of ovarian epithelial cancer, the expression of MTA2 in 4 ovarian cell lines were detected by semi-quantitative RT-PCR and Western-blot assays. MTA2 expression in normal, borderline, benign and malignant epithelial o varian tissues was immunohistochemically examined. The expression of MTA2 mRNA and protein was detected in all of 4 cell lines of ovarian epithelial cancer. The expression of MTA2 mRNA and protein was higher in strong migration cell lines than in weak migration ones. In borderline and malignant ovarian tissues tested, MTA2 staining was dramatically stronger than in normal and benign tissues (P＜0.01). The expression levels in malignant ovarian tissues were significantly higher than that in borderline epithelial ovarian tissues (P＜0.01). The expression of MTA2 was correlated with clinical stage, histopathological grade and lymph node metastasis. It was concluded that the high expression of MTA2 was associated with more aggressive behaviors of epithelial ovarian cancer. MTA2 provides a novel indicator of ovarian cancer.